Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | CALML3 | P27482 | 1/20 | 0.48 |
| ▸ | SDHA | P31040 | 1/20 | 0.48 |
| ▸ | F10 | P00742 | 10/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6400506 | 0.91 | MAOA (0.49) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL6400513 | 0.91 | MAOA (0.49) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL8646554 | 0.91 | MAOA (0.45) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL7529132 | 0.88 | F10 (0.48) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL6397247 | 0.88 | MAOA (0.48) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL6397251 | 0.88 | MAOA (0.48) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL6402400 | 0.87 | MAOA (0.49) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL6402405 | 0.87 | MAOA (0.49) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL7519248 | 0.86 | MAOA (0.45) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL7520237 | 0.85 | F10 (0.49) | MAOAMAOBLMNAPTGS1CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020133022-A1 | Antibiotic oxazolidinone derivatives | SYNGENTA LIMITED (GB) | 2002-09-19 | — | — | US | claimed |
| US-5981528-A | Antibiotic oxazolidinone derivatives | ZENECA LIMITED | 1999-11-09 | — | — | US | claimed |
| US-20020133022-A1 | Antibiotic oxazolidinone derivatives | SYNGENTA LIMITED (GB) | 2002-09-19 | — | — | US | disclosed |
| US-6271383-B1 | USEFUL ACTIVITY AGAINST GRAM-POSITIVE PATHOGENS; IN PARTICULAR, AGAINST VARIOUS STRAINS EXHIBITING RESISTANCE TO VANCOMYCIN AND AGAINST E. FAECIUM STRAINS RESISTANT TO BOTH AMINOGLYCOSIDES AND CLINICALLY USED BETA-LACTAMS. | ZENECA LIMITED (GB) | 2001-08-07 | — | — | US | disclosed |
| US-5981528-A | Antibiotic oxazolidinone derivatives | ZENECA LIMITED | 1999-11-09 | — | — | US | disclosed |
| EP-0882042-A1 | ANTIBIOTIC OXAZOLIDINONE DERIVATIVES | AstraZeneca UK Limited (GB) | 1998-12-09 | — | — | EP | disclosed |
| WO-1997030995-A1 | ANTIBIOTIC OXAZOLIDINONE DERIVATIVES | ZENECA LIMITED (GB) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020133022-A1 | Antibiotic oxazolidinone derivatives | OXA1L, POLN, MRPL21 | MAOA 2791/4885MAOB 2698/4885LMNA 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.